American Medical Systems' US prostate trial begins, Euro launch ahead:
This article was originally published in Clinica
Executive Summary
American Medical Systems (AMS) has begun a phase I/II US trial of it AMS ProstaJect ethanol injection system for treating benign prostate hyperplasia (see Clinica No 942, p 22). The Minneapolis, Minnesota company expects to enrol patients from 13 US centres across the US. The transurethral device uses ethanol to ablate the cells of an enlarged prostate gland. AMS will launch the device in Europe this month.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.